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Abstract
Background: In chronic kidney disease patients, angiotensin receptor blockers (ARBs) have been known to increase
serum potassium (K) levels. On the other hand, it has been reported that in patients on maintenance dialysis, both
hyperkalemia and hypokalemia were related to poor prognosis. In this study, the prognosis with ARB treatment was
investigated using a prospective cohort of dialysis patients that were divided into two groups according to pre-dialysis
serum K levels: these were the low serum K group (below 4.6 mEq/L) and the high serum K group (4.6 mEq/L and
higher).
Methods: A total of 260 patients in our dialysis database were classified into four groups according to their serum K
level and ARB use. The survival curves of these groups were estimated by Kaplan–Meier method and compared using
a log-rank test. Using Cox regression model, prognostic factors for all-cause mortality were extracted from background
factors, including the three classifications; high serum K and ARB group that served as the control.
Results: In terms of all-cause mortality rates, the low serum K and ARB group had the highest, whereas the high serum
K and ARB group had the lowest. In the Cox regression model, all three classifications, except the control group, were
factors for poor prognosis.
Conclusions: In this study, pre-dialysis serum K level and ARB use affected all-cause mortality of dialysis patients.
Multi-center prospective randomized study will be needed in the future to validate our findings.
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Background
In recent years, angiotensin receptor blockers (ARBs)
have been widely used in Japan as first-line drugs for the
treatment of hypertensive patients on maintenance dia-
lysis. However, renin–angiotensin system (RAS) inhibi-
tors, including ARBs, have been reported to induce
critical hyperkalemia in normokalemic patients with
chronic kidney disease or heart failure [1, 2]. In dialysis
patients, excessive hyperkalemia has been known as one
of the causes of sudden death [3] and hypokalemia lower
than 4.0 mEq/L has been reported to be associated with
poor prognosis [4]. Therefore, the appropriate control of
pre-dialysis serum potassium (K) at a level of 4.6–
5.5 mEq/L is important for good prognosis in dialysis
patients [5].
At present, it is not clear whether the use of ARB is
one of the risk factors for fatal hyperkalemia, which may
affect the prognosis of dialysis patients. Furthermore, it
is also unclear whether the efficacy and safety of ARB
treatment are consistent, regardless of serum K levels, in
hypokalemic and hyperkalemic patients before dialysis.
In this study, we performed multivariate analysis on our
prospective cohort of dialysis patients to examine the as-
sociation between ARB treatment and prognosis in both
hypokalemic (serum K below 4.6 mEq/L) and normo- to
hyperkalemic (serum K 4.6 mEq/L or more) groups.
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This was a prospective cohort study that enrolled 309
out-patients on dialysis at Yoshikawa Clinic between
April 2006 and October 2010. Written informed consent
was obtained from the patients who were registered on a
dialysis database. The original cohort consisted of 309
patients; of these, 49 were excluded because of inappro-
priate prescriptions and transfer to another dialysis facil-
ity within less than 1 month from registration. The
remaining 260 patients (149 men and 111 women) were
included in the final cohort.
Hemodialysis (HD) was performed thrice weekly with
a standard technique. The dialysate contained 2.0 mEq/
L of K and 3.0 mEq/L of calcium. Dry weight estimates
were routinely measured in our institution based on
clinical signs of hydration, blood pressure pattern dur-
ing dialysis sessions, and cardiothoracic ratio on chest
radiograph. The protocol of this study was approved by
the ethics committee of our hospital. This investigation
conformed to the principles outlined in the Declaration
of Helsinki.
Investigation of therapeutic prognosis with ARB treatment
Eligible patients were followed up until October 2010
from the time of registration in our database. The sur-
vival curves of the ARB and non-ARB groups were esti-
mated by Kaplan–Meier method and compared. The
main outcome measured was all-cause mortality, the
prognostic factors of which were extracted by Cox re-
gression model using descriptive variables, such as age,
gender, co-morbidities, vintage of dialysis, presence of
atrial fibrillation (AF) or ST–T segment changes on elec-
trocardiogram (ECG), medication at the time of registra-
tion, pre-dialysis average systolic blood pressure (SBP)
and diastolic blood pressure (DBP) within 1 month after
registration, average dialysis efficiency (Kt/V), and aver-
age values of laboratory blood tests during the entire ob-
servational period.
Comorbidities included were diabetes mellitus, heart fail-
ure, ischemic heart disease, and stroke. Having diabetes
mellitus, as a comorbidity, was defined as following one or
more of the following criteria of the Japan Diabetes Society:
the primary cause of end-stage renal disease was diabetic
nephropathy; random blood sugar level over 200 mg/dL; or
HbA1c over 6.5 % in more than one occasion. Congestive
heart failure (CHF) was defined by a history of decompen-
sated heart failure or left ventricular ejection fraction of less
than 40 % on echocardiography. Coronary artery disease
(CAD) was defined by a history of myocardial infarction or
coronary stenosis confirmed by coronary angiography or
another imaging techniques. Stroke was defined as the
presence of definitive findings of cerebral infarction or
hemorrhage on computed tomography or magnetic reson-
ance imaging. Standard 12-lead ECG was recorded every3 months at our hospital; the nearest tracing to the time of
registration was used. Changes in ST–T segment on resting
ECG were evaluated by two investigators based on the
Minnesota code of 4–1 to 4–4 for ST depression and 5–1
to 5–3 for negative or flat T wave [6]. Medications used
were ARBs, angiotensin-converting enzyme inhibitors
(ACEi), calcium (Ca) channel blockers (CCBs), beta-
blockers (Beta-B), and vitamin D3 (VD). SBP and DBP were
recorded by a brachial sphygmomanometer in the supine
position every 30 min during dialysis sessions, and from the
time of registration, the monthly average values of SBP and
DBP at the beginning of every dialysis session were used.
Laboratory blood tests that were measured included
blood urea nitrogen (BUN), albumin (Alb), hemoglobin
(Hb), C-reactive protein (CRP), serum K, Ca, phosphorus
(P), total cholesterol (TC), blood sugar (BS), and hepatitis
C virus (HCV) antibody. Of these variables, serum K was
regarded as categorical data and was classified as 0 (serum
K below 4.6 mEq/L) or 1 (serum K equal to or more than
4.6 mEq/L). Measurements of Kt/V and laboratory
markers were performed twice a month; the average
values for each were calculated during the entire observa-
tional period.
Investigation of the relationship between pre-dialysis serum
K level and prognosis with ARB therapy
Eligible patients were classified into the following four
groups according to serum K levels and the use or non-
use of ARB: (1) ARB non-use and serum K below
4.6 mEq/L (group 1); (2) ARB use and serum K below
4.6 mEq/L (group 2); (3) ARB non-use and serum K equal
to or more than 4.6 mEq/L (group 3); and (4) ARB use
and serum K equal to or more than 4.6 mEq/L (group 4).
Survival curves of these four groups were estimated by the
Kaplan–Meier method and were compared. Using the
four groups as descriptive variables, multivariate analysis
using Cox regression model was performed to determine
the prognostic factors for all-cause mortality, cardiovascu-
lar mortality and non-cardiovascular mortality. Groups 1
to 3 were included in the analysis as binary variables, with
group 4 serving as the control.
Statistical analysis
Continuous variables were presented as mean ± standard
deviation. Categorical variables were reported as num-
bers and percentages. Continuous variables were com-
pared by paired Student’s t test; categorical variables
were compared by the chi-square test, as appropriate.
The differences among survival curves were tested for
significance by the log-rank test. Extraction of prognos-
tic factors was performed using Cox regression model,
according to the variable decrease likelihood ratio
method. Adjusted hazard ratios (HR) and their 95 %
confidence intervals (CI) were reported. A p value of less
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statistical analyses were performed by the Dr SPSS II
software program (v11.0.1J; SPSS Inc., 1991–2000).
Results
Therapeutic prognosis with ARB in all subjects
Table 1 shows the clinical and demographic characteris-
tics of the study population according to ARB use. A
total of 260 HD patients, comprising 149 men and 111
women with a mean age of 68.8 ± 6.33 years, partici-
pated in this study. The mean duration of HD therapy at
the time of enrollment was 5.61 ± 3.25 years. There were
89 patients with diabetes and 101 patients with ST–T
segment changes. Hypertension was diagnosed in 214
patients; 167 patients were in the ARB group and 93Table 1 Patient profile
Total
Age (Years old) 68.8 ±
Gender (M to F ratio) 149:11
Vintage of dialysis (Years) 5.61 ±
Diabetes 89
CAD 50
CHF 30
Stroke 21
SBP at the beginning of session (mmHg) 148.5 ±
DBP at the beginning of session (mmHg) 74.5 ±
BUN (mg/dL) 63.0 ±
Kt/V 0.96 ±
Alb (g/dL) 3.63 ±
Hb (g/dL) 10.0 ±
CRP (mg/dL) 1.00 ±
K (mEq/L) 5.0 ± 0
Ca (mg/dL) 8.6 ± 0
P (mg/dL) 5.3 ± 0
TC (mg/dL) 155.4 ±
Blood glucose (mg/dL) 123.4 ±
AF 21
Changes of ST–T segment in ECG 101
HCV infection 18
ACEI 20
ARB 167
CCB 186
beta-B 88
VD 157
Weekly dose of Erythropoietin/DW (U/w/kg) 119.7 ±
CAD coronary artery disease, CHF congestive heart failure, SBP systolic blood pressu
hemoglobin, CRP C-reactive protein, K serum potassium, Ca calcium, P phosphorus,
converting enzyme inhibitor, ARB angiotensin II receptor blocker, CCB calcium chanpatients were in the non-ARB group. At the beginning of
the dialysis, mean blood pressure was 148.5 ± 9.40 mmHg
for SBP and 74.5 ± 5.44 mmHg for DBP. Compared with
the non-ARB group, the ARB group showed significantly
higher mean SBP and DBP values and significantly higher
proportion of patients who also received CCBs, beta-Bs,
and VD. There were no statistically significant differences
between the ARB group and non-ARB group in terms of
age, gender, vintage of dialysis, comorbidities, laboratory
data, ECG changes, and frequency of ACEi prescription.
During a mean follow-up period of 3.28 ± 0.74 years,
69 patients died; 43 of these deaths were due to cardio-
vascular disease (Tables 1 and 2). All-cause mortality
rate was the same for ARB group (25.1 %) and non-ARB
groups (29.0 %). The time course of the relationshipARB
(+) (–) p value
6.33 68.1 ± 6.10 70.1 ± 6.71 0.234
1 95:72 54:39 0.855
3.25 5.63 ± 3.30 5.56 ± 3.18 0.939
63 26 0.112
37 13 0.109
18 12 0.609
13 8 0.817
9.40 153.2 ± 7.99 140.1 ± 10.3 <0.001
5.44 75.6 ± 5.16 72.4 ± 5.81 0.024
5.25 63.4 ± 5.16 62.5 ± 5.42 0.503
0.12 0.96 ± 0.11 0.96 ± 0.11 0.997
0.19 3.65 ± 0.17 3.60 ± 0.21 0.354
0.33 10.0 ± 0.32 10.1 ± 0.35 0.570
0.99 0.97 ± 1.10 1.07 ± 0.77 0.701
.3 5.0 ± 0.3 4.9 ± 0.3 0.053
.3 8.6 ± 0.3 8.5 ± 0.3 0.096
.4 5.3 ± 0.4 5.3 ± 0.5 0.928
18.4 154.8 ± 18.0 156.3 ± 19.1 0.769
19.9 122.4 ± 19.5 125.3 ± 20.9 0.576
10 11 0.098
71 30 0.105
10 8 0.428
12 8 0.683
167 0 –
139 47 <0.001
66 22 0.009
111 46 0.007
44.4 121.5 ± 44.5 116.6 ± 44.6 0.354
re, DBP diastolic blood pressure, BUN blood urea nitrogen, Alb albumin, Hb
TC total cholesterol, AF atrial fibrillation, HCV hepatitis C virus, ACEI angiotensin
nel blocker, beta-B beta receptor blocker, VD vitamin D3, DW dry weight
Table 2 Causes of death
ARB
Total (+) (−)
Cardiovascular death 43 27 16
CHF 9 6 3
Acute coronary syndrome 2 1 1
Cardiac sudden death 14 7 7
Cerebral infarction 8 5 3
Cerebral hemorrhage 4 2 2
Aortic or peripheral artery disease 6 6 0
Death of other cause 26 15 11
Infection 13 7 6
Hepatic failure 2 1 1
Malignancy 3 3 0
Others 8 4 4
Total 69 42 27
CHF congestive heart failure
Table 3 Prognostic factors in the eligible patients for all-cause
mortality
Exp(B) 95 % CI p value
Age (per +1 year old) 1.047 1.020–1.075 0.001
Gender (male) 2.114 1.172–3.813 0.013
SBP at the beginning of session
(per +1 mmHg)
1.018 1.004–1.032 0.012
Albumin (per +1 g/dL) 0.151 0.071–0.321 <0.001
CRP (per +1 mg/dL) 1.147 1.038–1.268 0.007
SK < 4.6 mEq/L 2.453 1.469–4.095 0.001
Blood glucose (per +1 mg/dL) 1.009 1.002–1.016 0.008
AF 2.586 1.221–5.474 0.013
VD 0.580 0.350–0.962 0.035
SBP systolic blood pressure, CRP C-reactive protein, SK serum potassium, AF
atrial fibrillation, VD vitamin D3
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groups (p = 0.420) (Fig. 1).
Multivariate analysis (Table 3) showed that treatment
with ARB was not an independent prognostic factor for
all-cause mortality. Age, gender, SBP at the beginning of
dialysis, serum levels of albumin, CRP, and BS, serum K
below 4.6 mEq/L, presence of AF on ECG, and intake of
VD were extracted as significant prognostic factors for
all-cause mortality.
Comparison of therapeutic prognosis with ARB according
to pre-dialysis serum K levels
Groups 1, 2, 3, and 4 comprised 27, 36, 66, and 131 pa-
tients, respectively (Table 4). Vintage of dialysis, SBP,Fig. 1 Kaplan–Meier survival analysis between ARB group and
non-ARB groupDBP, BUN, Kt/V, Alb, Hb, CRP, Ca, P, BS, and frequency
of prescriptions of CCB, Beta-B, and VD were signifi-
cantly different among these four groups. Group 4, as
the control for multivariate analysis, included patients
who have been on HD for a relatively longer time and
showed good nutritional status, low CRP levels, and high
frequency of CCB, Beta-B, and VD prescriptions. In
terms of all-cause mortality, patients in group 2 had the
highest rate, whereas those in group 4 had the lowest
(p < 0.001) (Fig. 2). Multivariate analysis showed that
groups 1–3 had high all-cause mortality rates (Table 5).
Age, SBP, Kt/V, Alb, CRP, BS, and presence of AF were
also determined as prognostic factors for all-cause mortal-
ity. In terms of cardiovascular mortality, groups 1 and 2
had high cardiovascular mortality rates and hazard ratio
was 3.469 (1.180–10.19, p = 0.024) in group 1 and 4.980
(2.117–11.71, p < 0.001) in group 2.
Discussion
Pre-dialysis serum K level is one of the prognostic fac-
tors in patients on dialysis. Hypokalemia has been re-
ported to be associated with poor prognosis in terms
of all-cause mortality; similarly, remarkable hyperkale-
mia has also been reported to evoke lethal arrhythmia
[4, 5]. Specifically, among patients on ARB use, those
with normokalemia or hyperkalemia before dialysis
had the lowest all-cause mortality rate, whereas those
with hypokalemia before dialysis showed the poorest
prognosis. On the other hand, for dialysis patients who
were not on ARB treatment, hyperkalemia before dia-
lysis was associated with better prognosis than for
those with hypokalemia before dialysis. In addition, the
characteristics of groups 1–3 were independent risk
factors that increased all-cause mortality.
Several studies have indicated that RAS inhibitors, in-
cluding ACEi and ARBs, decreased cardiovascular events,
ameliorated renal function decline, and decreased mortality
Table 4 Patient profile grouping by predialysis potassium and ARB treatment
Predialysis potassium
<4.6 mEq/L ≥4.6 mEq/L
ARB(−) ARB(+) ARB(−) ARB(+)
Group 1 Group 2 Group 3 Group 4 p value
(n = 27) (n = 36) (n = 66) (n = 131)
Age (Years old) 70.2 ± 7.19 72.7 ± 6.54 70.0 ± 6.56 66.8 ± 5.85 0.060
Gender (M to F ratio) 17:10 27:9 37:29 68:63 0.087
Vintage of dialysis (Years) 2.18 ± 2.07 3.67 ± 2.32 6.95 ± 3.31 6.17 ± 3.48 0.002
Diabetes 8 18 18 45 0.131
CAD 5 5 8 32 0.166
CHF 3 3 5 7 0.710
Stroke 4 5 4 8 0.230
SBP at the beginning of session (mmHg) 132.9 ± 11.6 153.7 ± 9.62 143.0 ± 9.43 153.0 ± 7.52 <0.001
DBP at the beginning of session (mmHg) 69.6 ± 5.03 73.3 ± 6.00 73.6 ± 6.04 75.3 ± 4.87 0.019
BUN (mg/dL) 59.4 ± 5.15 55.4 ± 5.23 63.7 ± 5.44 65.6 ± 4.58 <0.001
Kt/V 0.87 ± 0.09 0.83 ± 0.12 0.99 ± 0.11 0.99 ± 0.09 <0.001
Alb (g/dL) 3.55 ± 0.22 3.40 ± 0.23 3.62 ± 0.20 3.71 ± 0.14 <0.001
Hb (g/dL) 10.22 ± 0.39 9.75 ± 0.46 10.02 ± 0.34 10.11 ± 0.26 0.016
CRP (mg/dL) 1.45 ± 1.03 1.96 ± 2.09 0.91 ± 0.63 0.69 ± 0.54 0.004
K (mEq/L) 4.2 ± 0.2 4.2 ± 0.2 5.2 ± 0.2 5.2 ± 0.2 –
Ca (mg/dL) 8.3 ± 0.3 8.5 ± 0.2 8.6 ± 0.3 8.7 ± 0.3 0.027
P (mg/dL) 5.1 ± 0.6 4.6 ± 0.4 5.4 ± 0.4 5.5 ± 0.4 <0.001
TC (mg/dL) 164.5 ± 21.9 142.3 ± 15.6 152.8 ± 17.7 157.9 ± 18.3 0.083
Blood glucose (mg/dL) 131.3 ± 21.8 139.6 ± 25.3 122.9 ± 20.7 118.3 ± 17.3 0.040
AF 4 2 7 8 0.363
Changes of ST–T segment in ECG 6 16 24 55 0.230
HCV infection 2 4 6 6 0.464
ACEI 1 1 7 11 0.442
ARB 0 36 0 131 –
CCB 14 30 33 109 <0.001
beta-B 4 8 18 58 0.002
VD 12 19 34 92 0.010
Weekly dose of erythropoietin/DW (U/w/kg) 111.5 ± 41.9 146.4 ± 41.4 118.6 ± 45.9 114.6 ± 44.8 0.272
Observational period 2.66 ± 0.81 2.19 ± 0.74 3.40 ± 0.71 3.65 ± 0.66 <0.001
All-cause death 8 24 19 18 <0.001
Cardiovascular death 5 14 11 13 <0.001
CAD coronary artery disease, CHF congestive heart failure, SBP systolic blood pressure, DBP diastolic blood pressure, BUN blood urea nitrogen, Alb albumin, Hb
hemoglobin, CRP C-reactive protein, K serum potassium, Ca calcium, P phosphorus, TC total cholesterol, AF atrial fibrillation, HCV hepatitis C virus, ACEI angiotensin
converting enzyme inhibitor, ARB angiotensin II receptor blocker, CCB calcium channel blocker, beta-B beta receptor blocker, VD vitamin D3, DW dry weight
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patients, several reports have shown the suppressive effects
of RAS inhibitors on left ventricular hypertrophy; however,
whether or not antihypertensive therapy with RAS inhibi-
tors can ameliorate all-cause or cardiovascular mortality
remains to be determined [10]. A randomized trial on fosi-
nopril in 397 dialysis patients failed to show improved car-
diovascular prognosis [11]. In a meta-analysis ofrandomized controlled trials of peritoneal dialysis patients,
antihypertensive therapy with ACEi or ARB did not reduce
mortality rates and cardiovascular events [12]. A retro-
spective investigation on the efficacy ACEi or ARB for
good cardiovascular prognosis in 1950 dialysis patients did
not show an association between the use of these RAS in-
hibitors and reduction of cardiovascular events [13]. On
the other hand, a retrospective study based on the DOPPS
Fig. 2 Impact of serum potassium level above median on the relationship between ARB treatment and all-cause mortality
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study on 28,628 dialysis patients by Chan et al. [15] simi-
larly showed that the use of ARB was associated with re-
duction of mortality rates.
In this study, all patients had the same all-cause mor-
tality regardless of ARB; however, those who were on
ARB and had pre-dialysis normokalemia or hyperkale-
mia showed lower mortality than the others. From these
results, antihypertensive therapy with ARB would seem
to improve prognosis only in patients with pre-dialysis
serum K level of 4.6 mEq/L or more. Because low pre-
dialysis serum K (below 4.6 mEq/L) was a risk factor for
all-cause mortality in this study, it is necessary to deter-
mine whether the demonstrated efficacy of ARB in
group 4 was secondary to an increased serum K level or
was due to the suppression of the RAS.
Although there was no significant difference in pre-
dialysis serum K levels between the ARB and non-ARB
groups, normokalemic or hyperkalemic patients on
ARBs had lower mortality rates than did those who were
not on ARBs. Furthermore, our results on multivariateTable 5 Prognostic factors of eligible patients including three group
Exp
Age (per +1 year old) 1.0
SBP at the beginning of session (per +1 mmHg) 1.0
Kt/V (per +1.0) 0.2
Albumin (per +1 g/dL) 0.2
CRP (per +1 mg/dL) 1.1
Blood glucose (per +1 mg/dL) 1.0
AF 3.2
Group 1 (SK < 4.6 mEq/L, ARB(−)) 3.9
Group 2 (SK < 4.6 mEq/L, ARB(+)) 3.7
Group 3 (SK ≥ 4.6 mEq/L, ARB(−)) 2.4
SBP systolic blood pressure, CRP C-reactive protein, AF atrial fibrillation, SK serum poanalysis suggest that ARB treatment improved prognosis
regardless of serum K levels. However, the influence of
ARBs on serum K levels was not accounted for and may
have confounded the outcomes of our study population.
In pre-dialysis patients with renal failure, it is gener-
ally accepted that the frequency of hyperkalemia due to
ARB use may increase along with deterioration of renal
function [1]. In contrast, it has not been clarified
whether antihypertensive therapy with RAS inhibitors
is a risk factor for lethal hyperkalemia in dialysis pa-
tients. Knoll et al. reported that the risk for hyperkale-
mia in dialysis patients increased 2.1–2.3 times due to
the use of RAS inhibitors [16]. In other literature, the
relationship between the use of ARB and changes in
serum K was not shown in dialysis patients [17, 18].
This present study was observational and based on our
dialysis database; in addition, patients who were on
ARB at the time of registration to the database were
assigned to the ARB group. Therefore, changes in
serum K that may be secondary to ARB administration
have not been recorded. In all patients, univariates as explanatory factors
(B) 95 % CI p value
48 1.019–1.078 0.001
24 1.008–1.040 0.003
28 0.067–0.776 0.018
00 0.094–0.427 <0.001
63 1.055–1.281 0.002
07 1.000–1.013 0.043
44 1.549–6.795 0.002
57 1.599–9.794 0.003
07 1.889–7.277 <0.001
45 1.211–4.934 0.013
tassium
Fig. 3 Correlation between serum potassium (K) level and plasma
aldosterone level/plasma renin-activity (PAC/PRA) ratio
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tween ARB use and pre-dialysis serum K (p = 0.016);
conversely, multivariate linear regression analysis using
stepwise backward elimination did not demonstrate a
significant relationship between ARB use and serum K
(Table 6). Factors, such as age, vintage of dialysis, SBP,
BUN, Kt/V, Alb, P, and Beta-B use, were positively cor-
related with serum K. Among these related factors, SBP,
BUN, Kt/V, Alb, and P were indicators of nutritional
status, suggesting that serum K may also be associated
with nutritional status, regardless of ARB use. This as-
sociation between pre-dialysis serum K and nutritional
status was similarly suggested by Kovesdy et al. [7].
Furthermore, in a post hoc analysis of 4D, hypokalemia
was evaluated as one of the indicators of malnutrition
[19]. Consequently, RAS suppression by ARB use, ra-
ther than serum K changes, has been suggested to con-
tribute to the favorable prognosis of group 4 patients in
this study.
In this study, the difference in prognosis between hypo-
kalemic and normokalemic or hyperkalemic patients on
ARB may be explained by some humoral factors that
could have influenced the effect of serum K on therapeutic
prognosis of ARB. Based on previous literature, changes
in plasma aldosterone concentration (PAC) positively cor-
related with serum K level in anuric dialysis patients [20].
In this present study, measurement of PAC was inciden-
tally performed in nine patients during the observation
period; Fig. 3 shows a positive correlation of PAC/plasma
renin-activity ratio with serum K level in these patients.
Similarly, dependency of aldosterone secretion on serum
K level in dialysis patients was suggested in this study.
High levels of aldosterone induce vascular and organ
damage, such as atherosclerosis, renal fibrosis, myocardial
hypertrophy, and fibrosis [21]. In vascular smooth muscle
cells, the link between aldosterone and angiotensin II re-
ceptor was also reported [21]. The randomized aldactone
evaluation study (RALES) revealed that spironolactone re-
duced all-cause mortality in patients with severe heartTable 6 Correlation with serum potassium in the eligible
patients
Standardized B p value
Age 0.126 0.019
Vintage of dialysis 0.165 0.002
SBP at the beginning of session 0.161 <0.001
BUN 0.327 <0.001
Kt/V 0.221 <0.001
Albumin 0.164 0.003
Phosphorus 0.229 <0.001
Use of beta-B 0.129 0.008
SBP systolic blood pressure, BUN blood urea nitrogen, beta-B beta
receptor blockerfailure [22]. In a recent randomized study on dialysis pa-
tients, spironolactone reduced cardiovascular events and
deaths [23]. Consequently, excess secretion of aldosterone
due to hyperkalemia in groups 3 and 4 was inferred in this
study. It is possible that antihypertensive therapy with
ARB in group 4 suppressed aldosterone secretion or the
cross-talk with aldosterone receptor to reduce all-cause
mortality.
In contrast, low aldosterone secretion due to hypokal-
emia in groups 1 and 2 was inferred based on the finding
that ARB use with serum K below 4.6 mEq/L had in-
creased all-cause mortality. Low aldosterone level as a risk
factor for all-cause mortality was reported in dialysis pa-
tients by Kohagura et al. [24]. However, the therapeutic
prognosis of ARB in dialysis patients with hypokalemia or
low aldosterone levels has not been clarified at the mo-
ment. In hypokalemic dialysis patients, antihypertensive
therapy with ARB may further reduce aldosterone se-
cretion and increase all-cause mortality. Accordingly,
based on aldosterone levels, it is necessary to confirm
the therapeutic prognosis and appropriate use of ARB
in dialysis patients.
Regarding ACEI treatment, there was no significant
difference in the mortality risk among the four groups
according to serum K levels (4.6 mEq/L) and the use or
non-use of ACEI monotherapy and combination therapy
with ARB. Multiple analyses showed that groups 1–3 did
not have high all-cause mortality rates. However, the
number of patients with ACEI treatment was so small,
especially two patients in group 2. It will be necessary to
confirm the safety of ACEI treatment in patients with
serum K levels below 4.6 mEq/L.
Limitations: This was a single-center observational
study on a relatively small study population. Despite
using multiple methods to address potential bias, we
cannot rule out the possibility of residual confounding
factors that may have affected the outcomes of patients
on ARB use. In addition, the effects of dosage or
duration of antihypertensive therapy with ARB were not
addressed.
Conclusions
In conclusion, pre-dialysis serum K may influence the effi-
cacy of ARB on all-cause mortality. Hyperkalemic dialysis
patients were suggested as the best candidates for antihy-
pertensive therapy with ARB. In contrast, dialysis patients
with serum K below 4.6 mEq/L may need to reconsider
intake of antihypertensive agents other than ARBs. The
relationship between therapeutic prognosis with ARB and
serum K or aldosterone level must be confirmed by pro-
spective randomized studies in the future.
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